Novartis Initiates Phase III Trial of Ilaris to Treat COVID-19 Patients with Pneumonia
Novartis has initiated a Phase III clinical trial to examine the efficacy of utilizing canakinumab (Ilaris), an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia.
Central Repository Created for SARS-CoV 2 Clinical Trials
Inato, a marketplace that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials, has unveiled its anticovid platform, a comprehensive, central repository for all existing clinical trials for SARS-CoV 2 (the virus that causes COVID-19).
Study Suggests MMR Vaccine May Be Linked with Fewer Deaths from COVID-19
Epidemiological data suggests populations with the highest measles-mumps-rubella (MMR) vaccination rates often have the fewest deaths from COVID-19.
Coronavirus Relief Funds to Pay for Care for Uninsured
The U.S. Department of Health and Human Services (HHS) is using a $100 billion hospital and provider relief fund to pay hospitals at Medicare rates for uncompensated COVID-19 care for uninsured individuals.
In the Shadow of COVID-19, Will Other Vaccine Development Programs Be Left Behind?
As governments around the world ramp up COVID-19 prevention activities, are other diseases of international importance and their prevention programs suddenly on pause?
FDA Initiates Coronavirus Medical Countermeasures
The U.S. Food and Drug Administration (FDA) is taking critical actions to advance development of novel coronavirus medical countermeasures.
